“Considered by peers as ‘one of
the best generic Hatch-Waxman
litigation firms on the east coast.’”
– LMG Life Sciences
Visit our new blog at www.biosimilarsip.com
“Rothwell Figg is known for ‘meticulous patent drafting.’ Solely based in the capital, [Rothwell Figg] knows all the ins and outs of the D.C. scene and the USPTO.”
Post-Grant Trial Practice
“[This] compact yet heavy-hitting IP boutique has a client list that is the envy of many. Marquee names are drawn here for several compelling reasons: a persuasive win rate in high-stakes cases, the advanced technical backgrounds of its litigators, great comparative value and renowned expertise in post-grant procedures.”
Visit our new blog at www.ptablaw.com
Represented Mylan Pharmaceutical in an infringement claim made by Bristol-Myers Squibb related to the drug Buspar (buspirone).
Bristol-Myers motioned to dismiss antitrust counterclaims made by Mylan. The Court ruled a summary judgment of noninfringement. The court also denied Bristol’s motion and suing Mylan on it, as well as held that Bristol had acted in an objectively unreasonable fashion in listing the metabolite patent for buspirone in the Orange Book.
Bristol-Myers settled the antitrust claims by paying $535 million, including $35 million to Mylan after an initial ruling in favor of Mylan, 29 State Attorneys General, and several plaintiff class action groups who had joined Mylan’s suit.
company’s IP case
Patent troll CyberFone Systems LLC alleges Warner Bros. Entertainment Inc., CBS Interactive Inc., and dozens of other companies infringed a patent which covers a system of entering transaction data into databases because it covers an abstract concept rather than a specific invention.
The district court granted defendants motion for summary judgment that CyberFone’s patent was invalid under USC 101. Rothwell Figg took the lead in drafting and arguing the motion on behalf of the defendants. Rothwell Figg also took the lead in drafting and arguing against CyberFone’s appeal to the Federal Circuit.
February 2014, the three-judge Federal Circuit panel upheld the District of Delaware’s ruling that invalidated a software patent that CyberFone Systems LLC; alleged the 81 companies including CBS, CNN and Fox News infringed because it was not patent eligible under 35 USC 101.
Shaping a 360°
defense for leading
360° IP Performance
Rothwell Figg is a multifaceted intellectual property firm for high-stakes legal matters.
- The Evolving Cryptocurrency Patent Landscape: Who is Winning the Race?
Rothwell Figg attorneys Martin M. Zoltick and Mark T. Rawls published an article in the March 2018 issue of Financier Worldwide Magazine titled "The evolving cryptocurrency patent landscape: who is winning the race?" Read the entire…
- Translating USPTO Case Law On Foreign-Language TMs
Foreign-language trademarks can be creative, appealing and exotic, but they can carry risks. The primary risk is the application of the doctrine of foreign equivalents. The Federal Circuit established the foreign equivalents doctrine in Palm Bay,…
- U.S. News – Best Lawyers® Names Rothwell Figg Among “Best Law Firms” in 2018 Edition
Rothwell Figg is honored to again receive Tier 1 and Tier 2 rankings by U.S. News & World Report and Best Lawyers “Best Law Firms.” Firms included in the 2018 “Best Law Firms” list are recognized…
- Rothwell Figg Attorneys Celebrate Return of Sacred Text with Government Officials
On Thursday, November 9, 2017, a team of Rothwell Figg attorneys celebrated the return of one of Chabad’s sacred texts along with rabbis of the Chabad-Lubavitch community and leaders of the U.S. Senate and House…
- Alternative Dispute Resolution
- Biologics and Biosimilars
- Biology and Biotechnology
- Cybersecurity, Privacy, and Data Protection
- Electrical and Computer
- Food and Drug Administration Practice
- Hatch-Waxman Litigation
- International Trade Commission
- Licensing and Transactions
- Media and Financial Services
- Patent Prosecution
- Post-Grant Trial Practice
- Software, E-Commerce and Business Methods
- Trademark Trial and Appeal Board
- Unfair Competition